Bristol-Myers Squibb Company (NYSE:BMY) is one of the top stocks sold by hedge funds. On July 28, Bristol Myers, in ...

The FDA has granted Breakthrough Therapy Designation to Bristol Myers Squibb (BMY) and SystImmune’s experimental drug iza-bren for treating advanced EGFR-mutant lung cancer after prior therapies fail, ...

Systlmmune and BMS’ ACD treats patients with previously treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer.

The 31st One Mind Music Festival on September 13, 2025 will be hosted at Staglin Family Vineyard in Rutherford, CA. The ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

Bristol-Myers Squibb offers strong cash flow, solid growth, and a high yield despite pricing pressure and pipeline risks. Read why BMY stock is a buy.

Bristol Myers Squibb recorded a one-time charge of $12.1 billion for the acquisition of Karuna in Q1’24, and expects its full-year earnings to fall to $0.75 per share at the mid-point of the ...

Bristol Myers Squibb's Cobenfy has been approved by the FDA as the first new treatment for schizophrenia in decades. The medication introduces a new approach by targeting M1 and M4 receptors ...

We expect Bristol Myers Squibb’s earnings to plunge to $0.76 in per share in 2024, versus $7.51 last year. However, this figure is expected to rebound to $7.30 in 2025.

This was the stock's fifth consecutive day of losses.